EZH2 and plasma cell myeloma: The inhibitors used in this present study, EPZ005687 and UNC1999, have been well characterised in previous studies and have been shown to be specific for EZH2 with few off-target effects.44, 47, 48 We were, therefore, able to study the effect of inhibition of EZH2 activity in myeloma more specifically than by taking a genetic knockdown approach, which would disrupt the PRC2 complex formation as a whole and potentially yield results that might not correlate with pharmacological inhibition in patients.